UBE2S and hepatocellular carcinoma: Additionally, the activation of H3K4me3 was found to be necessary for the UBE2S promoter to bind to FOXM1 and activate UBE2S transcription in hepatocellular carcinoma, thereby increasing resistance to oxaliplatin and 5-FU.